Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 12,734 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Recruiting Phase 2 Interventional

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

NCT07138274
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Interventions
Metyrapone 250 mg Oral Tablets, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 2:04 PM EDT
Terminated Phase 1 Interventional

To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors

NCT02410174
View directory record Official record
Conditions
Primary Tumor, Renal Cell Carcinoma
Interventions
Stereotactic Body Radiotherapy (SBRT)
Radiation
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 21, 2026, 2:04 PM EDT
Not listed Not applicable Interventional

MR/TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer

NCT04599218
View directory record Official record
Conditions
Prostate Disease, Elevated Prostate Specific Antigen, Family History of Prostate Cancer, Positive Digital Rectal Exam, Prostate Cancer
Interventions
Prostate Biopsy, MR US Fusion Guided Prostate Biopsy, MR/TRUS Fusion Guided Prostate Biopsy
Other · Device
Lead sponsor
Ardeshir Rastinehad
Other
Eligibility
18 Years and older · Male only
Enrollment
1,586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Lake Success, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 21, 2026, 2:04 PM EDT
Recruiting Phase 3 Interventional

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414
View directory record Official record
Conditions
Oligometastatic Prostate Cancer (OMPC)
Interventions
AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
39
States / cities
Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males

NCT00372008
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone
Drug
Lead sponsor
Acrux DDS Pty Ltd
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • La Mesa, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2008 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Penile Nerve Stimulation for Treatment of Delayed Ejaculation

NCT04115540
View directory record Official record
Conditions
Delayed Ejaculation
Interventions
TENS penile nerve stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

NCT01244568
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate cancer treatment DESI
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years and older · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

NCT00440648
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
sevelamer carbonate, sevelamer hydrochloride, sevelamer hydrochloride, sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Mobile, Alabama • Riverside, California • Greenwood Village, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer

NCT00253643
View directory record Official record
Conditions
Precancerous Condition, Prostate Cancer
Interventions
green tea catechin extract, fish oil, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Male only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
3
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 21, 2026, 2:04 PM EDT
Terminated No phase listed Observational

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

NCT00900068
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
immunoenzyme technique, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 2:04 PM EDT
Recruiting Phase 4 Interventional

Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones

NCT06003348
View directory record Official record
Conditions
Calcium Phosphate Kidney Stones
Interventions
OHCit- standard dose, Potassium Citrate, Placebo, OHCit- low dose
Dietary Supplement · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

NCT05511558
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-Fosgonimeton
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men

NCT01699178
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate, Transdermal testosterone gel (AndroGel)
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Calera, Alabama • Huntsville, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 21, 2026, 2:04 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Molecular MRI of the Fibrotic Heart

NCT02012725
View directory record Official record
Conditions
Healthy, Myocardial Fibrosis, Chronic Kidney Disease
Interventions
Arm 1 MRI with gadolinium
Drug
Lead sponsor
Moriel Vandsburger
Other
Eligibility
20 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rifampin Drug-Drug Interaction Study With Lurasidone HCl

NCT01082276
View directory record Official record
Conditions
Male, Healthy Normal Subjects
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02930889
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Prostate Artery Embolization
Device
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation

NCT00628550
View directory record Official record
Conditions
Cardiopulmonary Arrest, Cardiac Arrest
Interventions
Vasopressin, Epinephrine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 21, 2026, 2:04 PM EDT
Completed No phase listed Observational Results available

Retrospective Study on the Use, Efficiency, and Safety of the At-home Mosie Kit

NCT04646291
View directory record Official record
Conditions
Infertility, Infertility, Female, Infertility, Male
Interventions
Insemination with the Mosie Baby Kit
Device
Lead sponsor
Mosie Baby
Industry
Eligibility
Not listed
Enrollment
350 participants
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 21, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Implementing a Mobile Health Application for Women Veterans With Urinary Incontinence (MyHealtheBladder): Function QUERI 3.0

NCT07219433
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Implementation Strategy: Foundational Arm, Implementation Strategy: REACH Arm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

NCT03230838
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Interventions
Ceftolozane/Tazobactam, Meropenem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 21, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

NCT03439085
View directory record Official record
Conditions
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
Interventions
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 21, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158

NCT00849108
View directory record Official record
Conditions
Ischemia
Interventions
BMS747158
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Fremont, California • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 21, 2026, 2:04 PM EDT